Loading clinical trials...
Loading clinical trials...
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Conditions
Interventions
Everolimus
Everolimus
+1 more
Locations
11
United States
University of Alabama Hematology Oncology Clinic at Medical West
Birmingham, Alabama, United States
Northwestern University, Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
Cancer Care Center of Southern Indiana
Bloomington, Indiana, United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
IU Health Central Indiana Cancer Centers
Indianapolis, Indiana, United States
Metro Health Cancer Care
Wyoming, Michigan, United States
Start Date
December 1, 2010
Primary Completion Date
April 24, 2017
Completion Date
April 24, 2018
Last Updated
November 24, 2023
NCT05889195
NCT06857175
NCT05969860
NCT03317158
NCT04693377
NCT06770582
Lead Sponsor
Matthew Galsky
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions